Genelux, a privately-held, clinical stage biopharmaceutical company, has announced the company's lead product candidate, GL-ONC1, has been selected by Elsevier Business Intelligence, a global provider of healthcare industry information, as one of its 2013 "Top 10 Oncology Projects to Watch."
Elsevier considered various criteria when selecting the Top 10 Programs, including the history of the molecule or drug, the diversity of indications, initial and future, and multi-level partnering prospects.
"Select companies have been screened using a strict set of judging criteria for the Top 10 awards and represent what our committees consider among the most attractive opportunities the industry has to offer," said David Cassak, vice president, content, Elsevier Business Intelligence. "Winners have met rigorous criteria, including unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners and acquirers."